A 4-Week, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Clinical Study to Evaluate the Efficacy of Tegaserod in Relieving the Symptoms of Female Patients with Irritable Bowel Syndrome (IBS), Excluding Those with Predominant Di01/11/2004 - 07/31/2005 (PI)
Novartis Pharmaceuticals Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of the Efficacy and Safety of Tegaserod (6 mg b.i.d.), Administered Orally for 12 Weeks, To Male Patients with Chronic Constipation04/01/2004 - 02/01/2005 (PI)
Novartis Pharmaceuticals Corporation
Clinico-Pathological Analysis of Rectal Neuroendocrine Tumors07/01/2023 - 06/30/2024 (PI)
American College of Gastroenterology
Racial Factors in Symptom Patterns and Epidemiology of Irritable Bowel Syndrome07/01/2006 - 06/30/2007 (PI)
American College of Gastroenterology
Human Gastrin-Releasing Prg05/15/2000 - 02/28/2006 (PI)
NIH-NIDDK5 K08 DK02722-05 (A)
Mole. Mech. Of Abberrant Hu Ga07/01/2001 - 07/31/2005 (PI)
US Army
Human Gastrin Releasing Peptide receptor Gene Regulation08/04/2003 - 05/31/2005 (PI)
NIH-NIDDK5R03DK6320902A1
Regulation Of The Human Grp-R07/01/1999 - 06/30/2003 (PI)
AMER DIGESTIVE HLTH
Regulation Of The Human Grp-R07/01/1999 - 12/31/2001 (PI)
Harcourt General